GLP-1 dosing and titration explained
The short answer
GLP-1 medications are started low and increased in steps over weeks or months. This is called titration, and its purpose is tolerability — giving your digestive system time to adapt so the side effects stay manageable.
The starting dose is generally not intended to be an effective treatment dose. Dose schedules differ by product and by what is being treated, so follow the schedule your prescriber has given you and the Instructions for Use that came with your pen.
Why we don’t publish a dose chart
Dose strengths and escalation intervals differ between products, between the diabetes and weight-management versions of the same drug, and according to your response and other medications. Publishing a generic chart invites people to self-adjust against the wrong schedule. Your prescriber’s plan and your product’s current label are the correct references — we explain the principles instead.
What titration is for
The gastrointestinal effects of GLP-1 medications are dose-related: the higher the dose and the faster you get there, the more likely nausea, vomiting, and constipation become. Titration trades speed for tolerability.
The pattern is generally: a low starting dose held for a set period, then stepped increases at defined intervals, up to either a target maintenance dose or the highest dose you tolerate. Many people do well below the maximum dose — the goal is effect with acceptable side effects, not reaching the top of the range.
Why increases are spaced out
These medications are long-acting by design. After a change in dose, it takes weeks for drug levels to stabilise. Escalation intervals exist so that you experience the full effect of one dose before moving to the next — which is also why increasing early tends to stack side effects rather than accelerate progress.
If a dose increase is too rough
Struggling at a step up is common and worth reporting rather than enduring. Options a prescriber may consider include staying at the current dose longer before increasing again, or stepping back down to the previously tolerated dose. Both are normal clinical adjustments. What is not advisable is quietly stopping, doubling up to catch up, or splitting doses yourself.
Missed doses
Missed-dose instructions are specific to each product — they depend on the dosing interval and how long it has been. Your product’s Instructions for Use contains the rule for your medication, and your pharmacist can walk you through it. The general principles that hold across products:
- Never double up to make up for a missed dose.
- How long it has been matters — the guidance differs depending on how close you are to your next scheduled dose.
- After a longer gap, your prescriber may want you to restart at a lower dose and re-titrate, because tolerance fades.
Practical points
- Weekly products are taken on the same day each week, with or without food. Many people pick a day that lets any post-dose nausea fall on a quieter day.
- Rotate injection sites — see injection sites and rotation.
- Storage matters. These are biologics with specific refrigeration and in-use storage rules; check your product’s instructions.
- Never use someone else’s pen, or a product from an unverified source.
Contact your prescriber before changing anything if
- Side effects at a new dose are stopping you eating or drinking normally.
- You have missed multiple doses and are unsure how to restart.
- You also take insulin or a sulfonylurea — dose changes can affect hypoglycaemia risk.
- You are planning surgery or a procedure with sedation.
- You are pregnant, trying to conceive, or breastfeeding.
Guides in this section
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: Approved dosage and administration schedules, and missed-dose instructions, per product.
- Standards of Care in DiabetesAmerican Diabetes AssociationSupports: Clinical guidance on initiating and escalating GLP-1 receptor agonist therapy.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Product approvals and labeling for approved dose strengths.
- Diabetes, obesity and digestive-disease informationNational Institute of Diabetes and Digestive and Kidney Diseases (NIH)Supports: Background on pharmacological treatment of type 2 diabetes and obesity.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.